Radiopharm Theranostics Ltd 6-K, filed Nov 3, 2025

Radiopharm Theranostics Ltd (RADX)

6-K 2025-11-03 For: 2025-11-03

Added on April 08, 2026

About this 6-K

Radiopharm Theranostics Ltd filed this 6-K on November 3, 2025.

Exhibit Number		Description
99.1		Change of Director’s Interest Notice (RC)
99.2		Presenting at Deutsche Bank ADR Virtual Investor Conference

	RADIOPHARM THERANOSTICS LIMITED

Date: November 3, 2025	By:	/s/ Phillip Hains
		Phillip Hains
		Company Secretary

Name of Entity:	Radiopharm Theranostics Limited (ASX: RAD)
ABN:	57 647 877 889

Name of Director:	Riccardo Canevari
Date of Last Notice:	18 December 2024

Direct or Indirect Interest	Indirect

Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Indirect interest held via broker nominee account

Date of change	30 October 2025

No. of securities held prior to change			Shares	Options
		Direct	20,029,986	110,949,299
		Indirect	1,150,000	-
		Total	21,179,986	110,949,299

Class	RAD ORDINARY FULLY PAID SHARES

Number acquired			Shares	Options
		Direct	-	-
		Indirect	1,500,000	-
		Total	1,500,000	-

Number disposed			Shares	Options
		Direct	-	-
		Indirect	-	-
		Total	-	-

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$0.025 per share

+ See chapter 19 for defined terms.

01/01/2011	Appendix 3Y Page 1

No. of securities held after change			Shares	Options
		Direct	20,029,986	110,949,299
		Indirect	2,650,000	-
		Total	22,679,986	110,949,299

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market trade

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Appendix 3Y Page 2	01/01/2011

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

01/01/2011	Appendix 3Y Page 3

	●	Raised approximately A$35 million in capital through an institutional private placement to new Australian and international investors with a potential A$5 million through a Share Purchase Plan for existing shareholders in Australia and New Zealand.

	●	Reported preliminary data from the first three patients in a Phase 2b imaging clinical trial of RAD 101 that showed uptake in brain metastases from solid tumours, confirming proof-of-concept with Phase 2 topline results expected by H1 2026.

	●	Announced that the first cohort of patients in its Phase 1 clinical trial of RAD 202 (HER2) showed a higher-than-expected tumour uptake, with a second cohort of patients anticipated to be fully enrolled with data available by year-end 2025.

	●	Highlighted additional data from the first six patients in a Phase 1 clinical trial of RAD 204 (PDL-1), which showed promising tumour uptake.